Veozah and Trazodone Interaction: What Women Need to Know

Why This Combination Is Common in Midlife Women

Many women in perimenopause and post-menopause deal with two problems at the same time: new hot flashes and disrupted sleep. Fezolinetant (Veozah) targets the hot flashes. Trazodone is one of the most prescribed sleep aids in women over 45, used off-label at low doses (25 to 100 mg at bedtime) precisely because it causes less morning sedation than benzodiazepines. So the combination lands on a lot of prescription pads.

That overlap is understandable clinically. The Menopause Society 2023 position statement identifies fezolinetant as a recommended non-hormonal option for moderate-to-severe vasomotor symptoms (VMS), and low-dose trazodone has years of real-world use for sleep-maintenance insomnia in midlife women. But the two drugs share a metabolic pathway and layer sedative effects, which means you need a clear picture of the interaction before combining them.

Hot Flashes and Sleep: The Physiological Link

Hot flashes are not just an inconvenience. A 2023 analysis published in Menopause found that women with frequent nocturnal hot flashes spent significantly less time in slow-wave sleep compared with asymptomatic controls. Treating VMS can itself improve sleep architecture, which is why some women use fezolinetant alone. Others still need a dedicated sleep agent, and trazodone fills that role for many.

What Fezolinetant Actually Does

Fezolinetant blocks the neurokinin 3 (NK3) receptor in the hypothalamic KNDy (kisspeptin, neurokinin B, dynorphin) neuron circuit that drives the thermoregulatory dysfunction behind hot flashes. The key SKYLIGHT 1 and SKYLIGHT 2 trials demonstrated a reduction in moderate-to-severe hot flash frequency of approximately 60% versus placebo at week 12, with 45 mg once daily as the approved dose. The drug does not touch estrogen levels, which is central to its safety profile in women who cannot use hormone therapy.

The CYP1A2 Mechanism: Where the Real Interaction Lives

The core pharmacokinetic concern with this pair is CYP1A2. Fezolinetant is primarily metabolized by CYP1A2, the same enzyme responsible for metabolizing caffeine, duloxetine, and several antipsychotics. Trazodone itself is mainly a CYP3A4 substrate and CYP3A4/2D6 inhibitor, so it does not directly inhibit CYP1A2. That means trazodone is unlikely to raise fezolinetant plasma concentrations through a classic inhibition mechanism.

What Trazodone Does to Fezolinetant Levels

Because trazodone does not meaningfully inhibit CYP1A2, it is not expected to increase fezolinetant exposure in a clinically significant way. The Veozah FDA prescribing information explicitly contraindicates strong CYP1A2 inhibitors (such as fluvoxamine and ciprofloxacin), but trazodone does not belong to that class. So the pharmacokinetic arm of this interaction is low severity.

Where the Pharmacodynamic Interaction Matters More

Trazodone is a potent histamine H1 antagonist and a serotonin reuptake inhibitor at higher doses, producing marked sedation. Fezolinetant, in clinical trials, caused somnolence in roughly 2 to 3% of participants at 45 mg. The Veozah prescribing information lists somnolence as an adverse reaction, and combining any CNS-sedating drug amplifies that risk additively. In perimenopausal and postmenopausal women, who already experience disrupted sleep and fatigue, excess daytime sedation can impair driving and occupational function in ways that are easy to underestimate.

The combination's pharmacodynamic (PD) interaction severity is rated moderate in standard drug interaction databases. Moderate means the combination is not contraindicated but warrants clinical attention, dose review, and monitoring.

Does Trazodone Affect Liver Handling of Fezolinetant?

Fezolinetant carries an FDA-mandated hepatotoxicity warning. In the SKYLIGHT 4 long-term safety trial, alanine aminotransferase (ALT) elevations greater than three times the upper limit of normal occurred in about 2.3% of women taking fezolinetant 45 mg over 52 weeks. Trazodone itself has rare but documented hepatotoxicity in case reports. The two agents do not share a hepatic mechanism that would compound each other through direct pharmacokinetic combination, but running two drugs with independent hepatotoxic potential simultaneously means liver function tests become doubly important.

Monitoring Plan: What Should Actually Happen

Your prescriber should not simply co-prescribe these two drugs and send you on your way. Here is the monitoring framework that reflects both FDA labeling and clinical reasoning.

Liver Function Tests

The Veozah FDA label requires ALT, AST, and total bilirubin at:

• Baseline (before the first dose)
• Week 4
• Week 8
• Week 12

If you are also taking trazodone, that schedule should be followed without shortcuts. Any ALT elevation above three times normal should prompt a call to your prescriber the same day, not a wait-and-see approach.

Sedation Assessment

Track your daytime alertness in the first two weeks. Useful self-monitoring questions include:

• Are you falling asleep unintentionally during the day?
• Do you feel impaired when driving in the morning?
• Has your ability to concentrate at work changed?

If trazodone is being used at sleep doses of 50 mg or less, the additive sedation is usually manageable. At doses of 150 mg or higher (antidepressant range), the sedation overlap with fezolinetant warrants a frank conversation about timing and dose.

Sedation Timing Strategy

One practical approach that clinicians at WomanRx use: confirm that trazodone is dosed at bedtime and that fezolinetant is taken in the morning. The Veozah prescribing information does not specify a mandatory time of day, but morning dosing creates maximum temporal separation from trazodone's sedative peak (which occurs approximately 1 to 2 hours after ingestion). This does not eliminate the pharmacodynamic interaction but does reduce the period of peak overlap.

Sex-Specific Pharmacology: Why This Matters More for Women

Women metabolize drugs differently from men across the lifespan, and that reality is not always reflected in prescribing guidance. CYP1A2 activity is approximately 20 to 30% lower in women than men on average, and estrogen further suppresses CYP1A2 expression. That means fezolinetant clearance may vary depending on your hormonal status.

Perimenopause vs. Post-Menopause

During perimenopause, estrogen levels fluctuate unpredictably. CYP1A2 activity may be somewhat more variable than in stable post-menopause. After natural menopause, lower estrogen levels may allow CYP1A2 activity to rise slightly toward male norms, potentially slightly increasing fezolinetant clearance. The clinical significance of this shift has not been directly studied for fezolinetant. Per rule W6: the sex-specific PK data for fezolinetant in different hormonal stages is extrapolated from general CYP1A2 sex-difference literature rather than from dedicated fezolinetant PK substudies in perimenopausal women.

Body Composition and Volume of Distribution

Trazodone is highly lipophilic and distributes into adipose tissue. Women carry a higher body fat percentage on average than men, which can extend trazodone's effective duration and deepen sedation at equivalent doses. This is worth considering when your prescriber calibrates your trazodone dose, particularly if you are starting it at the same time as fezolinetant.

Menstrual Cycle Effects

Fezolinetant is indicated primarily for women in perimenopause and post-menopause, so active menstrual cycling is less commonly the relevant context. Still, some younger perimenopausal women with irregular cycles may use it. CYP1A2 activity fluctuates modestly across the menstrual cycle, suppressed by higher mid-cycle estrogen. The magnitude of this shift for fezolinetant has not been characterized, and the clinical effect is likely small given fezolinetant's once-daily fixed dose.

Pregnancy and Lactation Safety

Fezolinetant is contraindicated in pregnancy. This must be stated clearly.

Fezolinetant in Pregnancy

The Veozah prescribing information states that fezolinetant may cause fetal harm based on animal reproductive toxicity data. In rat studies, fezolinetant caused increases in fetal loss at doses producing exposures below the human therapeutic exposure. There are no adequate human pregnancy data. Because the NK3 receptor pathway is involved in GnRH pulsatility and reproductive signaling, interference during pregnancy carries theoretical concern beyond what animal data alone capture.

Women of reproductive potential must use effective contraception during fezolinetant treatment. The label does not specify a washout period after stopping, but given the drug's half-life of approximately 8 to 10 hours, plasma clearance is rapid. Standard guidance is to confirm negative pregnancy status before initiating and to counsel on contraception at every visit.

Trazodone in Pregnancy

Trazodone is classified as Pregnancy Category C, meaning animal studies showed adverse effects and there are insufficient human data. Observational data on first-trimester trazodone exposure are limited and have not consistently demonstrated major teratogenicity, but the evidence base is thin. If you discover you are pregnant while taking either drug, contact your prescriber immediately. Do not stop trazodone abruptly without guidance, as rebound insomnia and discontinuation symptoms can occur.

Lactation

Neither drug has strong human lactation data. Fezolinetant transfer into human breast milk has not been studied. Given the potential for NK3 receptor effects on prolactin-mediated milk production and the lack of infant safety data, the FDA label advises against breastfeeding during fezolinetant treatment.

Trazodone is present in breast milk in small amounts, with a relative infant dose estimated at under 3% in available case data. The clinical significance depends on infant age and feeding frequency. Discuss the benefit-risk balance with your prescriber rather than assuming either drug is automatically safe or unsafe during lactation.

Who This Combination Is Right For (and Who Should Think Twice)

Women Who May Be Appropriate Candidates

• Post-menopausal women with moderate-to-severe hot flashes who cannot use or prefer not to use hormone therapy, and who have concurrent sleep-maintenance insomnia managed with low-dose trazodone (25 to 50 mg at bedtime)
• Women with contraindications to hormone therapy (hormone-receptor-positive breast cancer history, personal or strong family history of venous thromboembolism) who need both VMS control and sleep support
• Women who have previously tried SSRIs or SNRIs for VMS with inadequate response or intolerable side effects and still need a sleep agent

Women Who Should Approach This Combination Cautiously or Avoid It

• Women with pre-existing liver disease or elevated baseline transaminases, given the independent hepatotoxicity signals for both agents
• Women taking strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin, enoxacin) alongside trazodone, because the fezolinetant plasma concentration could rise significantly and the sedative overlap could deepen
• Women taking higher-dose trazodone (150 mg or more) for depression, where sedation and orthostatic hypotension are already concerns and fezolinetant adds to the burden
• Women of reproductive potential who are not using reliable contraception
• Pregnant women (fezolinetant is contraindicated; see above)

PCOS Consideration

Women with PCOS represent a distinct population where fezolinetant has attracted research interest because hyperactive KNDy neuron signaling is implicated in PCOS pathophysiology. A 2023 study in the Journal of Clinical Endocrinology and Metabolism found that NK3 receptor antagonism reduced LH pulse frequency in PCOS. If a younger woman with PCOS is prescribed fezolinetant off-label, the interaction profile with trazodone remains the same, but the contraception requirement and potential effects on the reproductive axis need explicit discussion given her reproductive goals.

Other Veozah Drug Interactions You Should Know

The trazodone question rarely arrives alone. Women asking about this specific combination often have additional medications. Here are the interactions that carry higher severity than the trazodone pairing.

Strong CYP1A2 Inhibitors (Contraindicated With Fezolinetant)

The Veozah label lists strong CYP1A2 inhibitors as contraindicated. These include:

• Fluvoxamine (sometimes prescribed for OCD or perimenopausal anxiety)
• Ciprofloxacin (common antibiotic)
• Enoxacin

If you are prescribed a course of ciprofloxacin while on Veozah, contact your prescriber. A short antibiotic course may require a temporary fezolinetant hold.

Moderate CYP1A2 Inhibitors (Use With Caution)

• Mexiletine
• Oral contraceptives containing estrogen (ethinyl estradiol suppresses CYP1A2 and can modestly raise fezolinetant exposure)
• Oral contraceptives are also relevant given the contraception requirement for reproductive-aged women on fezolinetant

Drugs With Additive Hepatotoxicity Risk

Any drug with independent hepatotoxic potential warrants extra liver monitoring when combined with fezolinetant. This list includes acetaminophen at high regular doses, methotrexate, azathioprine, and anti-fungals like fluconazole. Trazodone sits in the lower tier of this concern but still belongs on the radar.

Hypotensive and CNS-Depressant Combinations

Trazodone causes orthostatic hypotension, particularly at initiation. Fezolinetant does not have a documented hypotensive signal, but women taking other antihypertensives, alpha-blockers, or low-dose naltrexone (increasingly popular in the midlife wellness space) should flag every concurrent medication.

Practical Counseling Points Before You Start

Your prescriber should cover these before you pick up your first Veozah prescription alongside trazodone. If they have not, bring this list to your next appointment.

1. Confirm your baseline liver panel (ALT, AST, bilirubin). If you do not have one from the past 6 months, get one before starting.
2. Know the LFT schedule: week 4, week 8, week 12. Put the appointments in your calendar now.
3. Take fezolinetant in the morning and trazodone at bedtime. Do not adjust this on your own.
4. Avoid alcohol in the first few weeks. Alcohol adds another sedative layer and independent hepatic stress.
5. Tell your prescriber immediately if you notice jaundice, dark urine, or right-upper-quadrant pain. These are hepatotoxicity red flags that require same-day contact, not a scheduled follow-up.
6. If you are in reproductive years or perimenopausal with intact ovarian function, confirm contraception is in place before starting fezolinetant. The FDA label is explicit on this.
7. Report daytime somnolence at your first follow-up. If it is significant, the trazodone dose is the more adjustable variable because its sleep dose range (25 to 100 mg) has room to titrate down.